Supplementary Table 1. Characteristics of All Included Studies

Authors (year)	Year of study	Country	Study design	ITB (n)	Control (n)	Reference standard	Tests	AUROC	Sensitivity (%)	Specificity (%)
Pulimood (1999)[1]	1986–1996	India	Retrospective	20	20	NA	Tissue pathology[c]	-	40.0	100.0
Gan (2002)[2]	1990–2000	China	Retrospective	39	30	Composite[b]	Tissue AFB Tissue PCR Tissue pathology	-	14.3 57.1 17.9	100.0 100.0 100.0
Patel (2004)[3]	1994–2002	India	Retrospective	250	10	Composite	Tissue AFB Tissue culture Tissue pathology	-	18.4 13.2 44.8	100.0 100.0 100.0
Amarapurkar (2004)[4]	2001	India	Retrospective	60	20	Composite	Tissue AFB Tissue PCR Tissue pathology	-	13.3 21.6 8.4	100.0 95.0 100.0
Pulimood (2005)[5]	1996–2000	India	Prospective	33	31	Composite	Tissue AFB Tissue culture Tissue pathology	-	6.1 18.2 36.4	100.0 100.0 100.0
Balamurugan (2006)[6]	2003–2005	India	Prospective	18	30	Composite	Stool PCR	-	88.8	100.0
Zhou (2006)[7]	1990–2004	China	Retrospective	30	30	Histopathology	Tissue pathology	-	100.0	100.0
Kirsch (2006)[8]	1984–2004	South Africa	Retrospective	18	25	Composite	Tissue pathology	-	22.0	100.0
Pulimood (2008)[9]	NA	India	Retrospective	20	20	Composite	Tissue AFB Tissue PCR Tissue pathology	-	35.0 30.0 30.0	100.0 95.0 100.0
Amarapurkar (2008)[10]	2002–2004	India	Prospective	26	26	Composite	Tissue culture Tissue PCR Tissue pathology	-	23.1 65.3 34.6	100.0 100.0 100.0
Lee (2009)[11,a]	2007–2009	South Korea	Retrospective	14	22	NA	Tissue PCR Tissue pathology IGRA (QFT)	-	15.4 21.4 85.7	100.0 100.0 95.5
Moon (2009)[12,a]	2006–2008	South Korea	NA	30	41	Composite	Tissue pathology IGRA (QFT)	-	20.0 90.0	100.0 85.4
Ramadass (2010)[13]	2005–2006	India	Prospective	24	44	Composite	Tissue culture Stool PCR	-	45.8 79.2	100.0 88.7
Jin (2010)[14]	1996–2007	South Korea	Retrospective	55	42	Composite	Tissue PCR Tissue pathology	-	45.5 26.9	88.1 100.0
Kim (2011)[15]	2007–2008	South Korea	Prospective	75	72	Composite	Tissue AFB Tissue culture Tissue pathology IGRA (QFT)	-	6.7 5.3 14.7 67.2	100.0 100.0 100.0 90.6
Dutta (2011)[16]	2006–2007	India	Prospective	30	30	Composite	Tissue AFB Tissue pathology	-	45.8 8.3	100.0 100.0
Yu (2012)[17]	2001–2010	China	Retrospective	43	53	Composite	Tissue pathology	-	13.3	100.0
Li (2012)[18]	2008–2010	China	Prospective	19	65	Composite	Tissue AFB IGRA (T-SPOT)	-	5.3 84.2	100.0 75.4

(Continued to the next page)

https://doi.org/10.5217/ir.2025.00098

Supplementary Table 1. Continued

Authors (year)	Year of study	Country	Study design	ITB (n)	Control (n)	Reference standard	Tests	AUROC	Sensitivity (%)	Specificity (%)
Sharma (2013)[19]	2008–2010	India	Prospective	40	30	Composite	Tissue AFB	-	5.0	100.0
							Tissue culture		1.0	100.0
							Tissue PCR		77.5	100.0
Lei (2013)[20]	2023–2011	China	Retrospective	88	103	NA	Tissue AFB	-	10.8	100.0
							Tissue PCR		57.5	92.7
							IGRA (T-SPOT)		85.7	92.5
Hallur (2013)[21]	2010–2011	India	Prospective	40	56	Composite	Tissue AFB	-	20.0	100.0
							Tissue culture		60.0	100.0
							Tissue PCR		87.5	96.4
Baek (2013)[22,a]	2007–2011	South Korea	NA	31	64	NA	IGRA (T-SPOT)	-	100.0	78.1
Fei (2014)[23]	2010–2013	China	Prospective	29	36	Composite	Tissue PCR	-	55.2	94.4
							Tissue pathology		10.3	100.0
							Stool PCR		82.2	91.7
Thomas (2014)[24,a]	2011–2013	India	Retrospective	21	29	Composite	Tissue pathology	-	28.6	100.0
Panackel (2014)[25,a]	NA	India	Prospective	18	37	NA	Tissue pathology	-	27.8	100.0
							IGRA (QFT)		94.4	83.8
Kim (2014)[26]	2001–2010	South Korea	Retrospective	18	21	Composite	IGRA (QFT)	-	27.8	95.2
He (2014)[27,a]	NA	China	NA	40	108	NA	IGRA (T-SPOT)	-	95.0	82.4
Erzin (2014)[28,a]	2003–2013	Turkey	Retrospective	20	109	NA	Tissue AFB	-	35.0	100.0
							Tissue culture		90.0	100.0
							Tissue PCR		83.3	96.3
Sekine (2015)[29]	2001–2012	Japan	Retrospective	50	132	Composite	Tissue AFB	0.69	38.0	100.0
							Tissue culture	0.75	50.0	100.0
							Tissue PCR	0.63	25.0	100.0
							Tissue pathology	0.54	8.2	99.1
							Stool AFB	0.67	36.8	96.2
							Stool culture	0.74	47.4	100.0
							Stool PCR	0.62	23.1	100.0
Zhang (2015)[30]	2013–2014	China	Prospective	31	92	Composite	IGRA (T-SPOT)	-	96.8	91.3
Shin (2015)[31,a]	2007–2013	South Korea	Retrospective	53	239	NA	IGRA (T-SPOT)	-	92.5	79.6
Huang (2015)[32]	2011–2012	China	Prospective	40	25	Composite	IGRA (T-SPOT)	-	95.0	100.0
Kumar (2017)[33]	2013–2014	India	Prospective	37	62	Composite	Tissue AFB	-	2.7	100.0
							Tissue culture		2.7	100.0
							Tissue Xpert MTB/RIF		8.1	100.0
							Tissue pathology		16.2	100.0
Bae (2017)[34]	2011–2015	South Korea	Prospective	40	40	Composite	IGRA (QFT)	-	75.0	95.0
Wu (2018)[35]	2013–2016	China	Prospective	86	153	Composite	Tissue AFB	-	9.3	100.0
							Tissue pathology		10.5	100.0
							IGRA (T-SPOT)		83.7	74.5
Mehta (2018)[36]	2014–2016	India	Prospective	70	112	Composite	Tissue culture	-	52.8	100.0

(Continued to the next page)

Supplementary Table 1. Continued

Authors (year)	Year of study	Country	Study design	ITB (n)	Control (n)	Reference standard	Tests	AUROC	Sensitivity (%)	Specificity (%)
Malik (2018)[37]	2015–2016	India	Prospective	32	18	Composite	Tissue AFB	-	6.2	100.0
							Tissue culture		9.3	100.0
							Tissue PCR		87.5	100.0
							Tissue pathology		3.1	100.0
Elleuch (2018)[38,a]	2005–2016	Tunisia	Retrospective	22	56	Composite	IGRA (QFT)	-	66.6	84.0
Xu (2019)[39]	2015–2018	China	Prospective	33	23	NA	IGRA	-	87.9	82.6
Sharma (2019)[40,a]	NA	India	Prospective	80	50	NA	Tissue AFB	-	2.5	100.0
							Tissue culture		7.5	100.0
							Tissue PCR		82.5	100.0
Meng (2019)[41]	2012–2017	China	Prospective	56	87	Composite	IGRA (T-SPOT)	-	73.2	85.1
Kumar (2019)[42]	2014–2015	India	Prospective	24	26	NA	Tissue AFB	-	4.2	100.0
							Tissue PCR		12.5	100.0
He (2019)[43]	2011–2017	China	Prospective	69	143	Composite	IGRA	-	89.9	88.8
Bellam (2019)[44]	2018	India	Retrospective	25	15	Composite	Tissue AFB	-	4.0	100.0
							Tissue Xpert MTB/RIF		32.0	100.0
							Tissue pathology		4.0	100.0
Alex (2020)[45,a]	NA	India	Retrospective	9	30	NA	Tissue Xpert MTB/RIF	-	71.4	78.1
Zhao (2020)[46]	2015–2018	China	Retrospective	35	272	Composite	IGRA	0.811	94.3	91.5
Sharma (2020)[47]	2016–2018	India	Prospective	35	30	Composite	Tissue AFB	-	5.7	100.0
							Tissue culture		14.3	100.0
							Tissue PCR		68.6	100.0
Paulose (2021)[48]	2016–2018	India	Retrospective	35	391	Composite	Tissue culture	-	94.3	100.0
							Tissue Xpert MTB/RIF		40.0	100.0
Lu (2021)[49]	2013–2020	China	Retrospective	84	84	Composite	Tissue AFB	-	16.0	100.0
							Tissue pathology		9.5	100.0
							IGRA		90.5	85.7
Fei (2021)[50]	2016–2018	China	Prospective	42	46	Composite	Tissue culture	-	7.1	100.0
							Tissue Xpert MTB/RIF		14.3	100.0
							Tissue pathology		10.7	100.0
Zeng (2022)[51]	2011–2020	China	Retrospective	43	90	Composite	Tissue pathology	-	7.0	100.0
							IGRA (T-SPOT)	0.926	92.2	93.0
Sharma (2022)[52]	2011–2021	India	Prospective	30	20	Composite	Tissue AFB	-	6.7	100.0
							Tissue culture		16.7	100.0
							Tissue PCR		83.3	100.0
							Tissue Xpert MTB/RIF		30.0	100.0
Li (2022)[53]	2014–2019	China	Retrospective	105	109	Composite	IGRA (T-SPOT)	-	81.0	50.5
Sachdeva (2023)[54]	2014–2021	India	Retrospective	59	49	Composite	IGRA (QFT)	0.66	40.7	75.5
Pateria (2023)[55]	2019–2021	India	Prospective	18	82	NA	Tissue culture	-	16.6	100.0
							Tissue Xpert MTB/RIF		33.3	100.0

[a]Abstract.
[b]Composite reference standard consists of compatible clinical, endoscopic finding, radiologic findings, histopathology, microbiologic tests and response to anti-tuberculosis.
[c]Histopathology of caseous necrosis or caseous granuloma.
ITB, intestinal tuberculosis; AUROC, area under the receiver operating characteristic curve; NA, not available; AFB, acid- fast bacilli; PCR, polymerase chain reaction; IGRA, interferon- gamma release assay.